252 related articles for article (PubMed ID: 30541168)
1. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
[TBL] [Abstract][Full Text] [Related]
2. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
[TBL] [Abstract][Full Text] [Related]
3. Effective detection of BRAF
Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
[TBL] [Abstract][Full Text] [Related]
5. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma.
Mochizuki H; Shapiro SG; Breen M
PLoS One; 2015; 10(12):e0144170. PubMed ID: 26649430
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or urogenital tract carcinoma.
Heilmann RM; McNiel EA; Grützner N; Lanerie DJ; Suchodolski JS; Steiner JM
BMC Vet Res; 2017 Apr; 13(1):112. PubMed ID: 28431528
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib).
Kim JH; Ahn DH; Moon JS; Han HJ; Bae K; Yoon KA
Vet Q; 2021 Dec; 41(1):153-162. PubMed ID: 33764261
[TBL] [Abstract][Full Text] [Related]
8. BRAF
Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
[TBL] [Abstract][Full Text] [Related]
9. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
10.
Sakai K; Maeda S; Saeki K; Yoshitake R; Goto-Koshino Y; Nakagawa T; Nishimura R; Yonezawa T; Matsuki N
Vet Pathol; 2020 Jan; 57(1):56-65. PubMed ID: 31640537
[TBL] [Abstract][Full Text] [Related]
11. Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.
Mochizuki H; Shapiro SG; Breen M
Vet Pathol; 2016 Jul; 53(4):764-72. PubMed ID: 26574558
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
[TBL] [Abstract][Full Text] [Related]
14. Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas.
Grassinger JM; Merz S; Aupperle-Lellbach H; Erhard H; Klopfleisch R
Vet Sci; 2019 Mar; 6(1):. PubMed ID: 30893857
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
Gedon J; Kehl A; Aupperle-Lellbach H; von Bomhard W; Schmidt JM
Vet Comp Oncol; 2022 Jun; 20(2):449-457. PubMed ID: 34878687
[TBL] [Abstract][Full Text] [Related]
17. [Detection of BRAF mutation in canine prostatic diseases].
Grassinger JM; Aupperle-Lellbach H; Erhard H; Merz S; Klopfleisch R
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2019 Oct; 47(5):313-320. PubMed ID: 31627222
[TBL] [Abstract][Full Text] [Related]
18. Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
Finotello R; Schiavo L; Ressel L; Frohmader A; Silvestrini P; Verin R
J Comp Pathol; 2019 Jul; 170():1-9. PubMed ID: 31375151
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
Kent MS; Zwingenberger A; Westropp JL; Barrett LE; Durbin-Johnson BP; Ghosh P; Vinall RL
BMC Vet Res; 2017 Nov; 13(1):339. PubMed ID: 29141625
[TBL] [Abstract][Full Text] [Related]
20. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
Mochizuki H; Breen M
Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]